Aridis Pharmaceuticals Inc. (ARDS): Price and Financial Metrics


Aridis Pharmaceuticals Inc. (ARDS)

Today's Latest Price: $7.02 USD

0.28 (-3.84%)

Updated Jun 3 6:55pm

Add ARDS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ARDS Stock Summary

  • The ratio of debt to operating expenses for Aridis Pharmaceuticals Inc is higher than it is for about only 0.37% of US stocks.
  • With a price/sales ratio of 74.63, Aridis Pharmaceuticals Inc has a higher such ratio than 97.46% of stocks in our set.
  • As for revenue growth, note that ARDS's revenue has grown -62.93% over the past 12 months; that beats the revenue growth of just 2.24% of US companies in our set.
  • Stocks that are quantitatively similar to ARDS, based on their financial statements, market capitalization, and price volatility, are ALPN, GRTS, PTI, UMRX, and SYBX.
  • ARDS's SEC filings can be seen here. And to visit Aridis Pharmaceuticals Inc's official web site, go to www.aridispharma.com.
ARDS Daily Price Range
ARDS 52-Week Price Range

ARDS Stock Price Chart More Charts


ARDS Price/Volume Stats

Current price $7.02 52-week high $12.40
Prev. close $7.30 52-week low $3.80
Day low $7.02 Volume 700
Day high $7.03 Avg. volume 10,571
50-day MA $6.78 Dividend yield N/A
200-day MA $6.59 Market Cap 62.64M

Aridis Pharmaceuticals Inc. (ARDS) Company Bio


Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The company was founded in 2003 and is based in San Jose, California.


ARDS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ARDS Latest Social Stream


Loading social stream, please wait...

View Full ARDS Social Stream

Latest ARDS News From Around the Web

Below are the latest news stories about Aridis Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARDS as an investment opportunity.

Aridis Pharmaceuticals Announces First Quarter 2020 Results

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate results for the first quarter ended March 31, 2020.

Yahoo | May 12, 2020

Will Aridis Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Aridis Pharmaceuticals

Yahoo | May 7, 2020

Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP)

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the enrollment of its first COVID-19 patient in the Company's ongoing Phase 3 clinical trial of AR-301, a monoclonal antibody against S. aureus induced pneumonia in patients who were already on mechanical ventilators.

Yahoo | May 4, 2020

Aridis Pharmaceuticals to Participate in Maxim Group's Infectious Disease Virtual Conference

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today its participation in Maxim Group's Infectious Disease Virtual Conference being held on May 5, 2020. Vu Truong, Ph.D., Chief Executive Officer, will be a speaker on two panels entitled "Non-antibiotic Anti-infectives" and "COVID-19 (Therapeutics)."

Yahoo | April 29, 2020

Can Aridis Pharmaceuticals’ APEX Platform Be Used to Target Coronavirus? Analyst Weighs In

If nothing else, the COVID-19 pandemic has spurred vast cooperation in the healthcare space. Having said that, it remains unclear as to what approach will be the most effective in stopping the deadly virus from continuing its romp around the world.Antiviral treatments such as remdesivir have garnered substantial attention, and while they are certainly promising with respect to their potential to slow the virus down, they won’t necessarily be able to stop COVID-19's spread completely. As was the case with other viral outbreaks like H1N1 in 2009 and Ebola in 2014, some healthcare officials argue that immune-based therapies like monoclonal antibody (mAb) cocktails and vaccines are our best bet.Enter Aridis Pharmaceuticals (ARDS), which is already up 37% year-to-date. Maxim analyst Jason Mc...

Yahoo | April 15, 2020

Read More 'ARDS' Stories Here

ARDS Price Returns

1-mo -14.49%
3-mo 10.20%
6-mo 39.14%
1-year -16.14%
3-year N/A
5-year N/A
YTD 57.75%
2019 -59.87%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching ARDS

Want to see what other sources are saying about Aridis Pharmaceuticals Inc's financials and stock price? Try the links below:

Aridis Pharmaceuticals Inc (ARDS) Stock Price | Nasdaq
Aridis Pharmaceuticals Inc (ARDS) Stock Quote, History and News - Yahoo Finance
Aridis Pharmaceuticals Inc (ARDS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8021 seconds.